全文获取类型
收费全文 | 4518篇 |
免费 | 232篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 189篇 |
妇产科学 | 55篇 |
基础医学 | 554篇 |
口腔科学 | 40篇 |
临床医学 | 245篇 |
内科学 | 1483篇 |
皮肤病学 | 56篇 |
神经病学 | 356篇 |
特种医学 | 116篇 |
外科学 | 633篇 |
综合类 | 10篇 |
预防医学 | 81篇 |
眼科学 | 89篇 |
药学 | 256篇 |
中国医学 | 3篇 |
肿瘤学 | 596篇 |
出版年
2024年 | 6篇 |
2023年 | 35篇 |
2022年 | 87篇 |
2021年 | 115篇 |
2020年 | 70篇 |
2019年 | 90篇 |
2018年 | 100篇 |
2017年 | 104篇 |
2016年 | 123篇 |
2015年 | 108篇 |
2014年 | 127篇 |
2013年 | 189篇 |
2012年 | 286篇 |
2011年 | 360篇 |
2010年 | 209篇 |
2009年 | 170篇 |
2008年 | 286篇 |
2007年 | 296篇 |
2006年 | 318篇 |
2005年 | 329篇 |
2004年 | 308篇 |
2003年 | 285篇 |
2002年 | 257篇 |
2001年 | 47篇 |
2000年 | 35篇 |
1999年 | 53篇 |
1998年 | 56篇 |
1997年 | 49篇 |
1996年 | 36篇 |
1995年 | 35篇 |
1994年 | 49篇 |
1993年 | 51篇 |
1992年 | 21篇 |
1991年 | 23篇 |
1990年 | 12篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 10篇 |
1985年 | 2篇 |
1984年 | 5篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1976年 | 1篇 |
1975年 | 4篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1969年 | 1篇 |
排序方式: 共有4805条查询结果,搜索用时 15 毫秒
131.
Miyazaki K Kamata H Kimura H Okina S Ishii R Osaka M Danbara M Horie R Higashihara M 《[Rinshō ketsueki] The Japanese journal of clinical hematology》2012,53(7):686-690
The IDSA guideline for management of febrile neutropenic patients updated in 2010 recommends monotherapy with anti-pseudomonal-lactam agents, including piperacillin-tazobactam (PIPC/TAZ) for high-risk patients. However, clinical studies of PIPC/TAZ are limited in Japanese patients. In this study, we conducted an open-labeled non-randomized prospective trial to examine the efficacy and safety of PIPC/TAZ as an empirical treatment for Japanese patients with febrile neutropenia. Forty-nine febrile episodes in neutropenic patients excluding those undergoing allogeneic stem cell transplantation (high risk 36, low risk 13) were analyzed. The overall response rate was 71%, and no significant differences between the high-risk and the low-risk group were observed (high risk 72%, low risk 69%). Neither PS nor usage of G-CSF affected the response rate. No major side effects were observed in the study. The efficacy and the safety profile of PIPC/TAZ treatment were comparable to those in other previous Western studies. In conclusion, this study suggests PIPC/TAZ is effective and well tolerated as an initial empirical treatment for febrile neutropenic Japanese patients. 相似文献
132.
Minobu Shichiji Yasushi Ito Keiko Shimojima Hidetsugu Nakamu Hirokazu Oguni Makiko Osawa Toshiyuki Yamamoto 《American journal of medical genetics. Part A》2013,161(4):850-855
The 2q23.1 deletion syndrome has been recently recognized as a neurodevelopmental disorder associated with intellectual disability, epilepsy, and autism spectrum disorder. Recently, methyl‐CpG‐binding domain 5 gene (MBD5), located in the 2q23.1 region, has been considered as a single causative gene of this syndrome. We report on a female patient with a de novo reciprocal translocation between chromosomes 2 and 5. Chromosomal microarray testing revealed a cryptic 896 kb deletion that included MBD5. Although clinical manifestations of this patient are compatible with those of patients with 2q23.1 deletion syndrome, a focal pachygyria revealed by brain magnetic resonance imaging has never been observed in the previously reported cases. Obesity caused by hyperphagia was observed in our patient and 28% of the previously reported patients with the 2q23.1 deletion syndrome. For better medical management, appropriate dietary guidance against hyperphagia should be given to the patients' family. © 2013 Wiley Periodicals, Inc. 相似文献
133.
Conventional hemorrhoidectomy is applied for the treatment of prolapsing internal hemorrhoids. Recently, less-invasive treatments such as sclerotherapy using aluminum potassium sulphate/tannic acid (ALTA) and a procedure for prolapse and hemorrhoids (PPH) have been introduced. We compared the results of sclerotherapy with ALTA and an improved type of PPH03 with those of hemorrhoidectomy. Between January 2006 and March 2009, we performed hemorrhoidectomy in 464 patients, ALTA in 940 patients, and PPH in 148 patients with second- and third-degree internal hemorrhoids according to the Goligher''s classification. The volume of ALTA injected into a hemorrhoid was 7.3 ± 2.2 (mean ± SD) mL. The duration of the operation was significantly shorter in ALTA (13 ± 2 minutes) than in hemorrhoidectomy (43 ± 5 minutes) or PPH (32 ± 12 minutes). Postoperative pain, requiring intravenous pain medications, occurred in 65 cases (14%) in hemorrhoidectomy, in 16 cases (1.7%) in ALTA, and in 1 case (0.7%) in PPH. The disappearance rates of prolapse were 100% in hemorrhoidectomy, 96% in ALTA, and 98.6% in PPH. ALTA can be performed on an outpatient basis without any severe pain or complication, and PPH is a useful alternative treatment with less pain. Less-invasive treatments are beneficial when performed with care to avoid complications. 相似文献
134.
Saruhara H Takata Y Usui Y Shiina K Hashimura Y Kato K Asano K Kawaguchi S Obitsu Y Shigematsu H Yamashina A 《Heart and vessels》2012,27(2):166-173
Obstructive sleep apnea (OSA) is not only a cause of hypertension; it also possibly affects the pathogenesis and progression of aortic disease because an inspiratory effort-induced increase in negative intrathoracic pressure generates mechanical stress on the aortic wall. The objective of the present study was to examine the incidence by location of OSA as a complication in patients with aortic aneurysm and patients with aortic dissection (AD). An overnight sleep study was conducted in the following study groups: the aortic disease group (n?=?95) consisting of patients with thoracic aortic aneurysm (TAA, n?=?32), patients with abdominal aortic aneurysm (AAA, n?=?36), and patients with AD (n?=?27); and a control group (n?=?32), consisting of patients with coronary risk factors who were matched with the aortic disease group for age, gender, and body mass index (BMI). The 3% oxygen desaturation index (ODI) was significantly higher in all the TAA, AAA, and AD groups (P?=?0.045, P?=?0.003, and P?=?0.005, respectively) than in the control group. The incidence of moderate to severe OSA [apnea hypopnea index (AHI) ??15 events/h] was significantly higher in the first three groups (P?=?0.026, P?=?0.001, P?=?0.003, respectively) than in the control group, while no significant difference was found between the TAA group and the AAA group with respect to these variables. Furthermore, no significant differences were found between the thoracic AD subgroup and the abdominal AD subgroup with respect to AHI and 3% ODI, as well as with respect to the incidences of moderate to severe OSA. Patients with TAA, patients with AAA, and patients with AD showed high incidences of moderate to severe OSA. Although this result suggests that OSA may be one of risks for aortic disease, unelucidated mechanism(s) other than negative intrathoracic pressure may be involved in the pathogenesis of aortic disease. 相似文献
135.
Sakamoto Y Sekino Y Yamada E Higurashi T Ohkubo H Sakai E Endo H Iida H Nonaka T Fujita K Yoneda M Koide T Takahashi H Goto A Abe Y Gotoh E Maeda S Nakajima A Inamori M 《World journal of gastroenterology : WJG》2012,18(26):3415-3419
AIM:To determine the effect of oral sumatriptan on gastric emptying using a continuous 13 C breath test(BreathID system).METHODS:Ten healthy male volunteers participated in this randomized,2-way crossover study.The subjects fasted overnight and were randomly assigned to receive a test meal(200 kcal/200 mL) 30 min after pre-medication with sumatriptan 50 mg(sumatriptan condition),or the test meal alone(control condition).Gastric emptying was monitored for 4 h after administration of the test meal by the 13 C-acetic acid breath test performed continually using the BreathID system.Then,using Oridion Research Software(β version),the time taken for emptying of 50% of the labeled meal(T 1/2) similar to the scintigraphy lag time for 10% emptying of the labeled meal(T lag),the gastric emptying coefficient(GEC),and the regression-estimated constants(β and κ) were calculated.The statistical significance of any differences in the parameters were analyzed using Wilcoxon’s signed-rank test.RESULTS:In the sumatriptan condition,significant differences compared with the control condition were found in T 1/2 [median 131.84 min(range,103.13-168.70) vs 120.27 min(89.61-138.25);P = 0.0016],T lag [median 80.085 min(59.23-125.89) vs 61.11 min(39.86-87.05);P = 0.0125],and β [median 2.3374(1.6407-3.8209) vs 2.0847(1.4755-2.9269);P = 0.0284].There were no significant differences in the GEC or κ between the 2 conditions.CONCLUSION:This study showed that oral sumatriptan significantly delayed gastric emptying of a liquid meal. 相似文献
136.
137.
138.
Hida S Chikamori T Tanaka H Igarashi Y Shiba C Usui Y Hatano T Yamashina A 《Circulation journal》2012,76(8):1942-1952
139.
140.
Kagawa T Kojima SI Shiraishi K Takashimizu S Nagata N Shiozawa H Nishizaki Y Ikeda A Tei Y Atsukawa K Kamochi JI Wasada M Numata M Arase Y Hirose S Yamada T Hata Y Watanabe N Morizane T Mine T 《Hepatology research》2012,42(4):351-358
Aim: The optimal ribavirin dose in the treatment of patients infected with hepatitis C virus (HCV) genotype 2 remains to be elucidated. We aimed to seek the optimal ribavirin dose required for this genotype in a randomized trial. Methods: We compared the efficacy and tolerability of the 24‐week peginterferon α‐2b (1.5 µg/kg/week) therapy in combination with a weight‐based higher dose (600–1000 mg) and lower dose (400–800 mg) of ribavirin for genotype 2 patients. Noninferior margin was set at 10%. Results: A total of 120 patients were randomized to a higher‐dose or a lower‐dose group. Sustained virological response (SVR) by intention‐to‐treat analysis was achieved in 47/58 (81.0%, 90% confidential interval [CI]: 72.6–89.5) patients in the higher‐dose group and 41/60 (68.3%, 90% CI: 58.5–78.2) patients in the lower‐dose group (difference, ?12.7%; 90% CI, ?25.7 to 0.3). Relapse rates were 10% and 21.6% in the higher‐dose and the lower‐dose groups, respectively. Multiple logistic regression analysis showed that ribavirin dose/kg body weight was the only significant predictor of SVR (≥9.5 mg/kg per day vs <9.5 mg/kg per day; odds ratio = 3.34; 95% CI, 1.41–7.92; P = 0.006). Twenty‐one (36.2%) in the higher‐dose group required ribavirin dose reduction because of anemia, whereas seven patients (11.7%) did in the lower‐dose group (P < 0.01). Three of the higher‐dose group and two of the lower‐dose group required premature termination of therapy. Conclusions: Weight‐based lower‐dose ribavirin regimen was not equivalent to the higher‐dose counterpart in the treatment of HCV genotype 2. We discourage treating these patients with low‐dose ribavirin regimens. The peginterferon therapy in combination with ribavirin at a weight‐based higher dose (600–1000 mg) remains the standard‐of‐care treatment for this genotype. 相似文献